Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 7/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3888518 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL305260 | 1.00 | — | — | |
| SCHEMBL10533402 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL4514650 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL305184 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL305058 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL153016 | 1.00 | — | — | |
| SCHEMBL2145601 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL22688944 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL31404556 | 1.00 | TSHR (0.50) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250249123-A1 | LIPIDS AND COMPOSITIONS THEREOF | GENERATION BIO CO. | 2025-08-07 | — | — | US | disclosed |
| US-12263228-B2 | Lipids and compositions thereof | GENERATION BIO CO. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240285796-A1 | CATIONIC LIPIDS AND COMPOSITIONS THEREOF | GENERATION BIO CO. | 2024-08-29 | — | — | US | disclosed |
| US-20240226325-A1 | CATIONIC LIPIDS AND COMPOSITIONS THEREOF | GENERATION BIO CO. | 2024-07-11 | — | — | US | disclosed |
| EP-4326235-A2 | CATIONIC LIPIDS AND COMPOSITIONS THEREOF | Generation Bio Co. (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-117545469-A | Cationic lipids and compositions thereof | 世代生物公司 | 2024-02-09 | — | — | CN | disclosed |
| US-20230320993-A1 | METHODS FOR ENCAPSULATING POLYNUCLEOTIDES INTO REDUCED SIZES OF LIPID NANOPARTICLES AND NOVEL FORMULATION THEREOF | GENERATION BIO CO. | 2023-10-12 | — | — | US | disclosed |
| CN-115417740-B | Preparation method of (R) -13-methyl heptadecane | 石家庄学院 | 2023-08-29 | — | — | CN | disclosed |
| CN-116437964-A | Methods for encapsulating polynucleotides into reduced size lipid nanoparticles and novel formulations thereof | 世代生物公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4181948-A2 | METHODS FOR ENCAPSULATING POLYNUCLEOTIDES INTO REDUCED SIZES OF LIPID NANOPARTICLES AND NOVEL FORMULATION THEREOF | Generation Bio Co. (US) | 2023-05-24 | — | — | EP | disclosed |
| US-6258841-B1 | ANTITUMOR AGENTS OR ANTIPROLIFERATION AGENTS | PARKER HUGHES INSTITUTE | 2001-07-10 | — | — | US | disclosed |
| EP-1091948-A2 | TUBULIN BINDING COMPOUNDS (COBRA) | Parker Hughes Institute (US) | 2001-04-18 | — | — | EP | disclosed |
| EP-1049687-A1 | THF INTERMEDIATES FOR ANNONACEOUS ACETOGENNINS | Parker Hughes Institute (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-2000000483-A9 | TUBULIN BINDING COMPOUNDS (COBRA) | WAYNE HUGHES INST (US) | 2000-03-30 | — | — | WO | disclosed |
| WO-2000000483-A2 | TUBULIN BINDING COMPOUNDS (COBRA) | PARKER HUGUES INSTITUTE (US) | 2000-01-06 | — | — | WO | disclosed |
| WO-1999036414-A1 | THF INTERMEDIATES FOR ANNONACEOUS ACETOGENINS | PARKER HUGHES INSTITUTE (US) | 1999-07-22 | — | — | WO | disclosed |
| US-5914410-A | Intermediates for annonaceous acetogenins | WAYNE HUGHES INSTITUTE (US) | 1999-06-22 | — | — | US | disclosed |
| CN-1046166-A | Contain the preparation method that the new 19-of 11 β-carbonated chain removes the first steroidal compounds | ROUSSEL UCLAF (FR) | 1990-10-17 | — | — | CN | disclosed |
| US-4801735-A | LEUKOTRIENE INHIBITORS | LILLY INDUSTRIES LIMITED (GB) | 1989-01-31 | — | — | US | disclosed |
| EP-0183532-A2 | Pharmaceutical compounds | Lilly Industries Limited (GB) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226325-A1 | CATIONIC LIPIDS AND COMPOSITIONS THEREOF | C1R, LRBA, LIPG | TSHR 1513/4885THRB 1118/4885DNM1 1295/4885 |
| US-12263228-B2 | Lipids and compositions thereof | C1R, LIPG, LRBA | TSHR 2035/4885THRB 1569/4885DNM1 1428/4885 |
| US-20250249123-A1 | LIPIDS AND COMPOSITIONS THEREOF | C1R, LIPG, LRBA | TSHR 2035/4885THRB 1569/4885DNM1 1428/4885 |
| US-20230320993-A1 | METHODS FOR ENCAPSULATING POLYNUCLEOTIDES INTO REDUCED SIZES OF LIPID NANOPARTICLES AND NOVEL FORMULATION THEREOF | POLN, POLRMT, LIPG | TSHR 4566/4885THRB 4771/4885DNM1 832/4885 |
| US-20240285796-A1 | CATIONIC LIPIDS AND COMPOSITIONS THEREOF | C1R, LRBA, LIPG | TSHR 1634/4885THRB 1233/4885DNM1 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.